Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study
Autore:
Stattin, P; Bylund, A; Rinaldi, S; Biessy, C; Dechaud, H; Stenman, UH; Egevad, L; Riboli, E; Hallmans, G; Kaaks, R;
Indirizzi:
Umea Univ Hosp, Dept Urol & Androl, S-90185 Umea, Sweden Umea Univ Hosp Umea Sweden S-90185 t Urol & Androl, S-90185 Umea, Sweden Umea Univ Hosp, Dept Geriatr, S-90185 Umea, Sweden Umea Univ Hosp Umea Sweden S-90185 p, Dept Geriatr, S-90185 Umea, Sweden Umea Univ Hosp, Dept Publ Hlth & Clin Med, S-90185 Umea, Sweden Umea Univ Hosp Umea Sweden S-90185 Hlth & Clin Med, S-90185 Umea, Sweden Int Agcy Res Canc, Lyon, France Int Agcy Res Canc Lyon FranceInt Agcy Res Canc, Lyon, France Hop Antiquaille, Cent Lab Biochem, Lyon, France Hop Antiquaille Lyon France Antiquaille, Cent Lab Biochem, Lyon, France Univ Helsinki, Cent Hosp, Dept Clin Chem, Helsinki, Finland Univ HelsinkiHelsinki Finland Hosp, Dept Clin Chem, Helsinki, Finland Karolinska Hosp, Dept Pathol, S-10401 Stockholm, Sweden Karolinska Hosp Stockholm Sweden S-10401 thol, S-10401 Stockholm, Sweden
Titolo Testata:
JOURNAL OF THE NATIONAL CANCER INSTITUTE
fascicolo: 23, volume: 92, anno: 2000,
pagine: 1910 - 1917
Fonte:
ISI
Lingua:
ENG
Soggetto:
BODY-MASS INDEX; IGF-I; DIETARY RESTRICTION; FACTOR (IGF)-I; UNITED-STATES; SERUM; HORMONE; MEN; AGE; SMOKING;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
48
Recensione:
Indirizzi per estratti:
Indirizzo: Stattin, P Umea Univ Hosp, Dept Urol & Androl, S-90185 Umea, Sweden Umea Univ Hosp Umea Sweden S-90185 drol, S-90185 Umea, Sweden
Citazione:
P. Stattin et al., "Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study", J NAT CANC, 92(23), 2000, pp. 1910-1917

Abstract

Background: Recent studies have suggested that men with elevated plasma levels of insulin-like growth factor-I (IGF-I) may have an increased risk of prostate cancer. Furthermore, IGF-binding proteins (IGFBPs) and insulin canmodulate the activity of IGF-I, In this study, we sought to determine the role of IGF-I as well as IGFBPs-1, -2, and -3 and insulin as possible etiologic factors for prostate cancer. Methods: We conducted a nested case-control study within the Northern Sweden Health and Disease Cohort Study. We measured levels of IGF-I, IGFBP-1, IGFBP-2, IGFBP-3, and insulin in plasma samples from 149 men who had a diagnosis of prostate cancer between I month and 10 Sears after blood collection and among 298 control men. All statistical tests are two-sided. Results: Case subjects had statistically significantly higher mean levels of IGF-I than control subjects (229 ng/mL; 95% confidence interval [CT] = 218-240 ng/mL] versus 214 ng/mL [95% CI = 208-221 ng/mL]; P = .02) and IGFBP-3 (2611 ng/mL [95% CI = 2518-2704 ng/mL] versus 2498ng/mL [95% CI = 2437-2560 ng/mL]; P = .04). Conditional logistic regression analyses showed increases in prostate cancer risk with rising levels of IGF-I (P-for trend = .02) and IGFBP-3 (P-for trend = .03). In case subjects younger than 59 years at the time of blood collection, the risk associated with increased IGF-I was higher (P-for trend = .01), whereas the risk associated with increased IGFBP-3 was lower (P-for trend = .44) than the corresponding risks in the full cohort. Prostate cancer risk was not associated with levels of IGFBP-1, IGFBP-2, or insulin. Conclusions: Prostate cancer risk is increased in men with elevated plasma IGF-I, This association was particularly strong in younger men in this study, suggesting that circulating IGF-I mag be specifically involved in the early pathogenesis of prostate cancer.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 20:08:14